Healthcare

Neuren Pharmaceuticals Limited (ASX:NEU) shares closed at AUD 14.44, falling 11.17 percent, on 3 February after its licensee, Acadia Pharmaceuticals Inc., released an update on the European regulatory status of trofinetide. The decline followed disclosure of a negative trend vote issued by the European …

Recce Pharmaceuticals Limited (ASX:RCE) has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR). The agreement expands the company’s ongoing collaborations with U.S. government research institutions focused on infectious disease and trauma care.

Shares of Biome Australia Ltd (ASX:BIO) moved higher on Monday, outperforming the broader market and the healthcare sector, after the company announced an expansion of its Canadian practitioner distribution network. The stock gained more than 6% during the session, even as the benchmark S&P/ASX …

4DMedical Limited (ASX:4DX) announced that University of Chicago Medicine has expanded its existingpartnershipto include commercial deployment of CT:VQ™, the company’s quantitative ventilation-perfusion imaging technology. University of Chicago Medicine is ranked among the leading U.S. hospitals for pulmonology and lung surgery and becomes the fifth …

FDA Clearance for NorthStar®Imricor Medical Systems, Inc. (ASX:IMR) announced on 29 January 2026, that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its NorthStar® Mapping System under the premarket notification process. This clearance makes NorthStar the first and only MRI-native 3D …

Resmed Inc. CDI (ASX:RMD) (NYSE:RMD) shares jumped by 3.13% to AUD 37.54 on 30 January 2026, following the release of the company’s financial results for the second quarter of fiscal year 2026, covering the three months ended 31 December 2025. The shares had been …

Immutep Limited (ASX:IMM) shares fell 2.95% to AUD 0.43 today, following a six-month surge of 58.15%. The Sydney-based immunotherapy company recently reported its quarterly activities for Q2 FY26, highlighting progress across multiple clinical trials, a strategic collaboration with Dr. Reddy’s, and a reinforced cash …